Drug prices compared at retail level U.S. vs other countries by multiplier 2020

In 2020, the estimated U.S. net prices for a selected group of 20 brand-name, single-source prescription drugs were over 4 times higher than gross prices paid at the retail level in Australia and France. U.S. prices were also 2.8 times higher than gross prices paid in Ontario, Canada. This statistic shows selected drug net prices in the United States compared to gross prices in Australia, Canada, and France at the retail level as of 2020.

U.S. net prices compared to gross prices in Australia, Canada, and France for selected drugs at retail level as of 2020, by multiplier*

Characteristic	Number of times higher (multiplier)
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

March 2021

More information

Region

Australia, Canada, France, United States

Survey time period

as of January 2020

Supplementary notes

* Estimated U.S. net prices reflect confidential rebates and other price concessions, information on such discounts was not publicly available for the comparison countries. Thus, the actual differences between U.S. prices and those of the other countries were likely larger than GAO estimates in this statistic.

The analysis was based on 20 brand-name, single-source prescription drugs that were among those with the highest total expenditures and use in the U.S. Medicare Part D program in 2017 and included on the formularies of all three selected comparison countries in 2020.
Prices for selected comparison countries—Australia, Canada (Ontario), and France—were prices listed on their respective public formularies from January 2020 and were converted to U.S. dollars at the relevant monthly Federal Reserve rates.
U.S. net prices at the retail level are the final amount paid to a retailer by all payers, such as a consumer and insurer, less rebates and other price concessions the payers receive from any source.

Citation formats